Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes.
The etiology of Parkinson's disease is unknown, but the gene involved in an autosomic recessive form of the disease with early onset has recently been identified. It codes for a protein with an unknown function called parkin. In the present study we produced a specific polyclonal antiserum against human parkin. Immunohistochemical analysis showed that parkin is expressed in neuronal perikarya and processes but also in glial and blood vessels in the primate brain (human and monkey). Electron microscopy indicated that parkin immunoreactivity is mostly located in large cytoplasmic vesicles and at the level of the endoplasmic reticulum. Parkin was expressed heterogeneously in various structures of the brain. It was detectable in the dopaminergic systems at the level of the perikarya in the mesencephalon but also in the striatum. However, parkin was also expressed by numerous nondopaminergic neurons. The staining intensity of parkin was particularly high in the hippocampal formation, the pallidal complex, the red nucleus, and the cerebellum. Comparison of control subjects with patients with Parkinson's disease and control animals with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated animals revealed a loss of parkin-immunoreactive neurons only in the substantia nigra pars compacta. Furthermore, the surviving dopaminergic neurons in the parkinsonian state continued to express parkin at a level similar to that observed in the control situation. These data indicate that parkin is a widely expressed protein. Thus, the degeneration of dopaminergic neurons in familial cases of Parkinson's disease with autosomal recessive transmission cannot be explained solely in terms of an alteration of this protein.
Zarate-Lagunes
M
M
INSERM U 289, Hôpital de la Salpêtrière, 47 Bd. de l'Hôpital, 75013 Paris, France.
Gu
W J
WJ
Blanchard
V
V
Francois
C
C
Muriel
M P
MP
Mouatt-Prigent
A
A
Bonici
B
B
Parent
A
A
Hartmann
A
A
Yelnik
J
J
Boehme
G A
GA
Pradier
L
L
Moussaoui
S
S
Faucheux
B
B
Raisman-Vozari
R
R
Agid
Y
Y
Brice
A
A
Hirsch
E C
EC
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000906:Antibodies / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D019556:COS Cells; D002144:Callithrix; D002522:Chlorocebus aethiops; D015259:Dopamine Agents; D004730:Endothelium, Vascular / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008025:Ligases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009457:Neuroglia / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism*; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism; D044767:Ubiquitin-Protein Ligases
D000906:Antibodies; D015259:Dopamine Agents; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D044767:Ubiquitin-Protein Ligases; D008025:Ligases